Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes please DWAC !
Sure hope so with my avg $52 !
Go DWAC
GLTA
100% ! Go DWAC !
Yes. Let’s try this again !
JNUG ready.
Need to with my avg over $50!
Hope wee see IMPP $4+ in 2024
Sounds good with my avg $4.24 !
(and of course will not add to avg down)...
GLTA
Cramer had Schaber on the show!
Nice work Schaber. Sub 50cent for Christmas.
Lying thief
Gold still running UP so JNUG going to have amazing week!
GLTA
Gold still running UP so GDXU going to have amazing week!
GLTA
SNGX always 2x PRs: 12/01/203: "December 01 2023 - 07:30AM PR Newswire
"HyBryte™ has potential to address a critical gap in treatment of early-stage CTCL
PRINCETON, N.J., Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that an article describing the potential use of HyBryte™ in the treatment of cutaneous T-cell lymphoma (CTCL) has been published in Frontiers in Drug Discovery. The mini-review summarizes findings about the use, mechanism and effectiveness of HyBryte™ in the treatment of CTCL with a particular emphasis on the ability of HyBryte™ to address the unmet medical need in patients with early-stage disease.
"With its chronic course and major impact on patient quality of life, CTCL is an orphan disease in urgent need of additional treatment options that are well-tolerated and safe over the long term," stated Brian Poligone, MD, PhD, Director of the Rochester Skin Lymphoma Medical Group, Fairport, NY. "Clinical studies with HyBryte™ have demonstrated its safety and effectiveness, with broad applicability across different lesion types, different skin tones and different disease stages. I know I can speak for my colleagues that have been involved with these studies when I say that the data generated to date has been extremely compelling."
"In treating CTCL, which is a chronic cancer with no cure, long-term safety is a strong driver of treatment choice. Most current treatment options for CTCL are associated with significant safety concerns, including black-box warnings. HyBryte™ treatment has demonstrated strong and rapid efficacy with a very benign safety profile," stated Richard Straube, MD, Senior Vice President and Chief Medical Officer of Soligenix. "Studies to date have indicated a substantial increase in efficacy with longer treatment with similar performance against both patch and plaque lesions. These results are derived from one of the largest studies ever conducted in CTCL and we believe HyBryte™ will be of significant benefit to patients living with this difficult disease."
Yeah I'm around $7 cost-basis as wouldn't throw any more at it...
(because of r/s)
GLTA
Please do the after lunch BIG run !
GLTA
SNGX 11/30 confirmation news the real deal?
Or another run up to dilute, r/s, and fail another 2-3 years?
One can only hope..
GLTA
“7:30a ET 11/30/2023 - PR Newswire
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Beh?et's Disease”
Seen it before.
Last I sold 20% was at $60…
Gold $2500-$3000 May see JNUG $100 again
JNUG $60+ coming back around…
GLTA
I saw no mention of r/s.
Surprisingly
SNGX low volume sell off? WTH?
GDXU such a deal $28 with gold $2020!
GLTA
JNUG such a deal $28 with gold $2020!
GLTA
Great letter. Seems no concern?
Update please CALC? Graybug seemd to have so much potential...
Nice work Schaber. Penny for your thoughts.
SNGX now penny stock pre split…
Seemed bit of interest pops this 9m float fast after hours…
Can only hope for good news next week…
GLTA
I still show DWAC o/s at 37.21m?
Did I miss a filing it jumped over 600m?!
100% same here!
SNGX Volume very low so fat lady hasn’t sung but definitely warming up…
SNGX 50 cent after hours must be leak of ANOTHER reverse split?…
I saw no dilution
The SEC accepted the $18m settlement.
August DAWC should get good…
GLTA
Eh... Whats 50 BILLION shares....
What in the world happening with TLSS dump today on high volume?
How is sale of 1 ship so negative for IMPP?
I can’t it’s stuck in 3 of my portfolios !!!
SNGX 7/11/2023: Phase 2a Study in Mild-to-Moderate Psoriasis
Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,announced today the expansion of its Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis after demonstration of biological effect in the initial five subjects. The study is expected to enroll at least an additional five subjects, exploring the use of SGX302 in the standard of care psoriasis setting, prior to undertaking the larger phase of the study.
https://mma.prnewswire.com/media/1768046/Soligenix_Logo.jpg
Evaluation of the initial five subjects enrolled demonstrated a clear biological signal, with the majority of patients recording an improvement in the PASI (psoriasis area and severity index) score. Enrolling additional patients will enable Soligenix to evaluate the use of SGX302 in the context of accelerated light treatment and additional adjunct treatment.
"Patients with mild-to-moderate disease do not qualify for the use of biologics and have fewer treatment options. The patients enrolled in this study all demonstrated clinical improvement and, with the experience gained in this first portion of the study, we anticipate being able to further improve responses as we move forward," stated Neal Bhatia, MD, Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego and Chair of the Company's Psoriasis MAB. "Having previously participated in the positive Phase 3 clinical trial of HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL), I have had a clinical interest in this novel therapy and am pleased that the Soligenix team is advancing synthetic hypericin in psoriasis where there remains an unmet medical need. Similar to CTCL, psoriasis is a chronic disease where the management of side effects and toxicities is as important as the management of the disease itself. Psoriasis affects more than 7.5 million patients in the U.S. alone, and 60-125 million people worldwide. Having treated psoriasis patients for over 20 years and seen first-hand how they struggle to find good treatment options, access to an additional effective and safe therapy would add significantly to patient care and quality of life for many people that are living with this disease. I look forward to working with my esteemed colleagues to support Soligenix in advancing this important development program forward."
"We are pleased with the initial results from our Phase 2a trial," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "The expansion of this psoriasis study continues our evaluation of synthetic hypericin into other disease indications, including non-orphan indications, where there remains an unmet medical need. Current estimates show as many as 60-125 million people worldwide living with the condition, with a global treatment market valued at approximately $15 billion in 2020 and projected to reach as much as $40 billion by 2027. The success of HyBryte™ in targeting malignant T-cells during CTCL clinical trials is a promising indicator of the ability of SGX302 to provide a much-needed approach for the treatment of mild-to-moderate psoriasis, also caused by dysregulated T-cells. We anticipate being in a position to report additional SGX302 study data before year-end, as well as the outcome of our ongoing discussions with the FDA regarding a feasible and executable trial design for a confirmatory Phase 3 study with HyBryte™ in the treatment of early stage CTCL."
100%. Thanks for posting!
Hope our new IMPP shares (CISS) hold above $3 !!!
GLTA
SNGX sell off 6/20 must be MORE bad news
Go CALC!
Maybe I’ll get my $40 pre split back!
Riding MULN out to set new record.
$20k down to $200 soon to be $2…